Skip to main content
. 2015 Jan 6;7:47–58. doi: 10.2147/IJWH.S74462

Table 3.

Selected toxicities reported from Phase III studies of eribulin

EMBRACE study (n=508)
301 Study (n=544)
Any grade% Grade 3% Grade 4% Any grade% Grade 3% Grade 4%
Hematologic toxicities
Neutropenia 52 21 24 54 25 21
Leukopenia 23 12 2 31 13 2
Anemia 19 2 <1 19 2 0
Thrombocytopenia NR NR NR 5 <1 0
Nonhematologic toxicities
Alopecia 45 35
Nausea 35 1 0 22 < 1 0
Vomiting 18 4 <1 12 < 1 <1
Diarrhea 18 0 0 14 1 0
Asthenia 54 8 1 15 4 <1
Peripheral neuropathy 35 8 <1 13 4 0
Febrile neutropenia 5 NR NR 2 2 <1
Hypersensitivity 1 NR NR NR NR NR

Abbreviations: NR, not reported; EMBRACE, the Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389.